Press release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first drug targeting disability progression in secondary progressive multiple sclerosis without relapses

▤ Summary

Sanofi has secured EU approval for Cenrifki (tolebrutinib) as the first medicine targeting disability progression in non-relapsing secondary progressive multiple sclerosis. The approval is based on phase 3 HERCULES data, supported by GEMINI 1 and 2 studies, and Sanofi says the safety profile remained consistent across the clinical program. Sanofi plans to make Cenrifki commercially available in Germany this year with physician support, risk-management controls, and a patient support program. The launch highlights an important unmet need in MS care and gives Sanofi a new commercial product in Europe.

▦ Linked Companies